International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 52

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in *Cumulative List No. 10, 2002* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 52

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la *Liste récapitulative No. 10, 2002* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 52

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en *Cumulative List No. 10, 2002* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

adecatumumabum

adecatumumab — immunoglobulin G1, anti-(human antigen 17-1A) (human monoclonal MT201 γ1-chain), disulfide with human monoclonal MT201 κ-chain, dimer

adécatumumab — immunoglobuline G1, anti-(antigène 17-1A de la molécule d'adhésion de la cellule épithéliale humain) ; dimère du disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal humain MT201

adecatumumab — inmunoglobulina G1, anti-(antígeno humano 17-1A) dímero del disulfuro entre la cadena γ1 y la cadena κ del anticuerpo monoclonal humano MT201

$C_{6552}H_{10080}N_{1740}O_{2052}S_{46}$

arformoterolum

arformoterol — *N*-{2-hydroxy-5-[(1*R*)-1-hydroxy-2-{[(2*R*)-1-(4-methoxyphenyl)= propan-2-yl]amino}ethyl)phenyl]formamide

arformotérol — (-)-*N*-[2-hydroxy-5-[(1*R*)-1-hydroxy-2-[[(1*R*)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]phényl]formamide

arformoterol — (-)-*N*-[2-hidroxi-5-[(1*R*)-1-hidroxi-2-[[(1*R*)-2-(4-metoxifenil)-1-metiletil]amino]etil]fenil]formamida

$C_{19}H_{24}N_2O_4$



banoxantronum

banoxantrone — 1,4-bis{[2-(dimethylazinoyl)ethyl]amino}-5,8-dihydroxy-9,10-anthraquinone

banoxantrone — 1,4-bis[[2-(diméthyloxydoamino)éthyl]amino]-5,8-dihydroxyanthracène-9,10-dione

banoxantrona — 1,4-bis[[2-(dimetiloxidoamino)etil]amino]-5,8-dihidroxiantraceno-9,10-diona

$C_{22}H_{28}N_4O_6$



batabulinum

batabulin — 2,3,4,5,6-pentafluoro-*N*-(3-fluoro-4-methoxyphenyl)= benzenesulfonamide

batabuline — 2,3,4,5,6-pentafluoro-*N*-(3-fluoro-4-méthoxyphényl)= benzènesulfonamide

batabulina — 2,3,4,5,6-pentafluoro-*N*-(3-fluoro-4-metoxifenil)bencenosulfonamida

$C_{13}H_7F_6NO_3S$



becampanelum

becampanel — [(7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)methylamino]= methylphosphonic acid

bécampanel — acide [[[(7-nitro-2,3-dioxo-1,2,3,4-tétrahydroquinoxalin-5-yl)méthyl]= amino]méthyl]phosphonique

becampanel — ácido [[[(7-nitro-2,3-dioxo-1,2,3,4-tetrahidroquinoxalin-5-il)metil]= amino]metil]fosfónico

$C_{10}H_{11}N_4O_7P$



beminafilum

beminafil — *trans*-4-{4-[(3-chloro-4-methoxybenzyl)amino][1]benzothieno=[2,3-*d*]pyrimidin-2-yl}cyclohexanecarboxylic acid

béminafil — acide *trans*-4-[4-[(3-chloro-4-méthoxybenzyl)amino]benzo=[4,5]thiéno[2,3-*d*]pyrimidin-2-yl]cyclohexanecarboxylique

beminafilo — ácido *trans*-4-{4-[(3-cloro-4-metoxibencil)amino][1]benzotieno=[2,3-*d*]pirimidin-2-il}ciclohexanocarboxílico

$C_{25}H_{24}ClN_3O_3S$



binodenosonum

binodenoson — 2-[(*E*)-(cyclohexylmethylene)hydrazino]adenosine

binodénoson — 2-[(*E*)-2-(cyclohexylméthylène)diazanyl]-9-β-D-ribofuranosyl-9*H*-purin-6-amine

binodenosón — 2-[(*E*)-2-(ciclohexilmetileno)diazanil]-9-β-D-ribofuranosil-9*H*-purin-6-amina

$C_{17}H_{25}N_7O_4$



certolizumabum pegolum

certolizumab pegol — immunoglobulin, anti-(human tumor necrosis factor α) Fab' fragment (human-mouse monoclonal CDP870 heavy chain), disulfide with human-mouse monoclonal CDP870 light chain, pegylated at Cys-221

certolizumab pégol — immunoglobuline, anti-(facteur α de nécrose tumorale humain) ; disulfure entre le fragment Fab' de la chaîne lourde et la chaîne légère de l'anticorps monoclonal de souris CDP870 humanisé pégylé

certolizumab pegol — inmunoglobulina, anti-(factor α de necrosis tumoral humano) fragmento Fab' (cadena pesada del anticuerpo monoclonal humanizado de ratón CDP870), disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón CDP870, pegilado

$C_{2115}H_{3252}N_{556}O_{673}S_{16}$ (peptide)

ciluprevirum

ciluprevir (2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-6-[(cyclopentyloxycarbonyl)amino]-2-({7-methoxy-2-[(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl}oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]=diazacyclopentadecine-14a(5*H*)-carboxylic acid

ciluprévir acide (2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-6-[[(cyclopentyloxy)carbonyl]amino]-2-[[7-méthoxy-2-[2-[(1-méthyléthyl)amino]thiazol-4-yl]quinoléin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tétradécahydrocyclopropa=[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadécine-14a(5*H*)-carboxylique

ciluprevir ácido (2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-6-[[(ciclopentiloxi)carbonil]amino]-2-[[2-[2-[(1-metiletil)amino]tiazol-4-il]-7-metoxi-quinolin-4-il] oxi]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahidrociclopropa=[*e*]pirrolo[1,2-*a*][1,4]diazaciclopentadecina-14a(5*H*)-carboxílico

$C_{40}H_{50}N_6O_8S$



clazosentanum

clazosentan *N*-{6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1*H*-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl}-5-methylpyridine-2-sulfonamide

clazosentan *N*-[6-(2-hydroxyéthoxy)-5-(2-méthoxyphénoxy)-2-[2-(1*H*-tétrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-méthylpyridine-2-sulfonamide

clazosentán *N*-[6-(2-hidroxietoxi)-5-metil-2-[2-(1*H*-tetrazol-5-il)piridin-4-il]pirimidin-4-il]-5-(2-metoxifenoxi)piridina-2-sulfonamida

$C_{25}H_{23}N_9O_6S$



clofarabinum

clofarabine — 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9*H*-purin-6-amine

clofarabine — 2-chloro-9-(2-désoxy-2-fluoro-β-D-arabinofuranosyl)-9*H*-purin-6-amine

clofarabina — 2-cloro-9-(2-desoxi-2-fluoro-β-D-arabinofuranosil)-9*H*-purin-6-amina

$C_{10}H_{11}ClFN_5O_3$



daglutrilum

daglutril — [(3*S*)-3-{1-[(2*R*)-2-ethoxycarbonyl-4-phenylbutyl]=cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl]acetic acid

daglutril — acide [(3*S*)-3-[[[1-[(2*R*)-2-(éthoxycarbonyl)-4-phénylbutyl]=cyclopentyl]carbonyl]amino]-2-oxo-2,3,4,5-tétrahydro-1*H*-1-benzazépin-1-yl]acétique

daglutrilo — ácido [(3*S*)-3-[[[1-[(2*R*)-2-(etoxicarbonil)-4-fenilbutil]ciclopentil]=carbonil]amino]-2-oxo-2,3,4,5-tetrahidro-1*H*-1-benzazepin-1-il]acético

$C_{31}H_{38}N_2O_6$



dextofisopamum

dextofisopam — (5*R*)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5*H*-2,3-benzodiazepine

dextofisopam — (+)-(5*R*)-1-(3,4-diméthoxyphényl)-5-éthyl-7,8-diméthoxy-4-méthyl-5*H*-2,3-benzodiazépine

dextofisopam — (+)-(5*R*)-1-(3,4-dimetoxifenil)-5-etil-7,8-dimetoxi-4-metil-5*H*-2,3-benzodiazepina

$C_{22}H_{26}N_2O_4$



doranidazolum

doranidazole	(2*RS*,3*SR*)-3-{[2-nitroimidazol-1-yl]methoxy}butane-1,2,4-triol
doranidazole	(2*RS*,3*SR*)-3-[(2-nitro-1*H*-imidazol-1-yl)méthyl]butane-1,2,4-triol
doranidazol	(2*RS*,3*SR*)-3-[(2-nitro-1*H*-imidazol-1-il)metil]butano-1,2,4-triol

$C_8H_{13}N_3O_6$



and enantiomer
et énantiomère
y enantiómero

ecopladibum

ecopladib	4-(2-{5-chloro-2-[2-(3,4-dichlorobenzylsulfonamido)ethyl]-1-(diphenylmethyl)-1*H*-indol-3-yl}ethoxy)benzoic acid
écopladib	acide 4-[2-[5-chloro-2-[2-[[(3,4-dichlorobenzyl)sulfonyl]amino]éthyl]-1-(diphénylméthyl)-1*H*-indol-3-yl]éthoxy]benzoïque
ecopladib	ácido 4-[2-[5-cloro-2-[2-[[(3,4-diclorobencil)sulfonil]amino]etil]-1-(difenilmetil)-1*H*-indol-3-il]etoxi]benzoico

$C_{39}H_{33}Cl_3N_2O_5S$



eglumetadum

eglumetad	(1*S*,2*S*,5*R*,6*S*)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
églumétad	acide (1*S*,2*S*,5*R*,6*S*)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylique
eglumetad	ácido (1*S*,2*S*,5*R*,6*S*)-2-aminobiciclo[3.1.0]hexano-2,6-dicarboxílico

$C_8H_{11}NO_4$



enzastaurinum

enzastaurin — 3-(1-methyl-1*H*-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1*H*-indol-3-yl}pyrrole-2,5-dione

enzastaurine — 3-(1-méthyl-1*H*-indol-3-yl)-4-[1-[1-(pyridin-2-ylméthyl)pipéridin-4-yl]-1*H*-indol-3-yl]-1*H*-pyrrole-2,5-dione

enzastaurina — 3-(1-metil-1*H*-indol-3-il)-4-[1-[1-(piridin-2-ilmetil)piperidin-4-il]-1*H*-indol-3-il]-1*H*-pirrol-2,5-diona

$C_{32}H_{29}N_5O_2$



esoxybutyninum

esoxybutynin — 4-(diethylamino)but-2-yn-1-yl (2*S*)-cyclohexyl(hydroxy)phenylacetate

ésoxybutynine — (2*S*)-cyclohexylhydroxyphénylacétate de 4-(diéthylamino)but-2-ynyle

esoxybutynina — (2*S*)-ciclohexilhidroxifenilacetato de 4-(dietilamino)but-2-inilo

$C_{22}H_{31}NO_3$



hormonum parathyroidum

parathyroid hormone — non glycosylated human parathyroid hormone, the origin should be indicated between brackets after the INN, for example (r. *E.coli*) for recombinant produced by *Escherichia coli*

hormone parathyroïde — hormone parathyroide humaine nonglycosylée, l'origine doit être indiquée entre parenthèses après la DCI, par exemple (r. *E. coli*) pour recombinante produite par *Escherichia coli*

hormona paratiroidea — hormona paratiroidea humana no glicosilada, el origen deberá, indicarse entre paréntesis después de la DCI, por ejemplo (r. *E. coli*) para la recombinante producida por *Escherichia coli*

$C_{408}H_{674}N_{126}O_{126}S_2$

H-Ser—Val—Ser—Glu—Ile—Gln—Leu—Met—His—Asn—Leu—Gly—
10
Lys—His—Leu—Asn—Ser—Met—Glu—Arg—Val—Glu—Trp—Leu—
20
Arg—Lys—Lys—Leu—Gln—Asp—Val—His—Asn—Phe—Val—Ala—
30
Leu—Gly—Ala—Pro—Leu—Ala—Pro—Arg—Asp—Ala—Gly—Ser—
40
Gln—Arg—Pro—Arg—Lys—Lys—Glu—Asp—Asn—Val—Leu—Val—
50 60
Glu—Ser—His—Glu—Lys—Ser—Leu—Gly—Glu—Ala—Asp—Lys—
70
Ala—Asp—Val—Asn—Val—Leu—Thr—Lys—Ala—Lys—Ser—Gln-OH
80

idursulfasum

idursulfase — α-L-iduronate sulfate sulfatase

idursulfase — sulfatase du sulfate de α-L-iduronate

idursulfasa — sulfatasa del sulfato de α-L -iduronato

$C_{2689}H_{4057}N_{699}O_{792}S_{14}$ *(subunit protein moiety reduced)*

SETQANSTTD ALNVLLIIVD DLRPSLGCYG DKLVRSPNID
QLASHSLLFQ NAFAQQAVCA PSRVSFLTGR RPDTTRLYDF
NSYWRVHAGN FSTIPQYFKE NGYVTMSVGK VFHPGISSNH
TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD GELHANLLCP
VDVLDVPEGT LPDKQSTEQA IQLLEKMKTS ASPFFLAVGY
HKPHIPFRYP KEFQKLYPLE NITLAPDPEV PDGLPPVAYN
PWMDIRQRED VQALNISVPY GPIPVDFQRK IRQSYFASVS
YLDTQVGRLL SALDDLQLAN STIIAFTSDH GWALGEHGEW
AKYSNFDVAT HVPLIFYVPG RTASLPEAGE KLFPYLDPFD
SASQLMEPGR QSMDLVELVS LFPTLAGLAG LQVPPRCPVP
SFHVELCREG KNLLKHFRFR DLEEDPYLPG NPRELIAYSQ
YPRPSDIPQW NSDKPSLKDI KIMGYSIRTI DYRYTVWVGF
NPDEFLANFS DIHAGELYFV DSDPLQDHNM YNDSQGGDLF
QLLMP

imidafenacinum

imidafenacin	4-(2-methyl-1*H*-imidazol-1-yl)-2,2-diphenylbutanamide
imidafénacine	4-(2-méthyl-1*H*-imidazol-1-yl)-2,2-diphénylbutanamide
imidafenacina	2,2-difenil-4-(2-metil-1*H*-imidazol-1-il)butanamida
	$C_{20}H_{21}N_3O$



lacosamidum

lacosamide	(2*R*)-2-(acetylamino)-*N*-benzyl-3-methoxypropanamide
lacosamide	(2*R*)-2-(acétylamino)-*N*-benzyl-3-méthoxypropanamide
lacosamida	(2*R*)-2-(acetilamino)-*N*-bencil-3-metoxipropanamida
	$C_{13}H_{18}N_2O_3$



lumiliximabum

lumiliximab	immunoglobulin G1, anti-(human immunoglobulin E receptor type II) (human-*Macaca irus* monoclonal IDEC-152 γ1-chain), disulfide with human-*Macaca irus* monoclonal IDEC-152 κ-chain, dimer
lumiliximab	immunoglobuline G1, anti-(récepteur de type II humain de l'immunoglobuline E) ; dimère du disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal chimérique homme-*Macaca irus* IDEC-152
lumiliximab	inmunoglobulina G1, anti-(receptor de tipo II humano de la inmunoglobulina E) ; dímero del disulfuro entre la cadena γ1 y la cadena κ del anticuerpo monoclonal quimérico hombre-*Macaca irus* IDEC-152
	$C_{6850}H_{10656}N_{1824}O_{2106}S_{50}$

maropitantum

maropitant	(2*S*,3*S*)-*N*-(5-*tert*-butyl-2-methoxybenzyl)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octan-3-amine
maropitant	(2*S*,3*S*)-*N*-[5-(1,1-diméthyléthyl)-2-méthoxybenzyl]-2-(diphénylméthyl)-1-azabicyclo[2.2.2]octan-3-amine
maropitant	(2*S*,3*S*)-*N*-[5-(1,1-dimetiletil)-2-metoxibencil]-2-(difenilmetil)-1-azabiciclo[2.2.2]octan-3-amina

$C_{32}H_{40}N_2O$



mubritinibum

mubritinib	1-(4-{4-[(2-{(*E*)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1*H*-1,2,3-triazole
mubritinib	1-[4-[4-[[2-[(*E*)-2-[4-(trifluorométhyl)phényl]éthényl]oxazol-4-yl]méthoxy]phényl]butyl]-1*H*-1,2,3-triazole
mubritinib	1-[4-[4-[[2-[(*E*)-2-[4-(trifluorometil)fenil]etenil]oxazol-4-il]metoxi]fenil]butil]-1*H*-1,2,3-triazol

$C_{25}H_{23}F_3N_4O_2$



muraglitazarum

muraglitazar	([(4-methoxyphenoxy)carbonyl]{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}amino)acetic acid
muraglitazar	acide [[(4-méthoxyphénoxy)carbonyl][4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]benzyl]amino]acétique
muraglitazar	ácido [[(4-metoxifenoxi)carbonil][4-[2-(2-fenil-5-metiloxazol-4-il)=etoxi]bencil]amino]acético

$C_{29}H_{28}N_2O_7$



nebentanum

nebentan	(*E*)-*N*-[6-methoxy-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]-2-phenylethenesulfonamide
nébentan	(1*E*)-*N*-[6-méthoxy-5-(2-méthoxyphénoxy)-2,2'-bipyrimidyl-4-yl]-2-phényléthènesulfonamide
nebentán	(1*E*)-2-fenil-*N*-[6-metoxi-5-(2-metoxifenoxi)-2,2'-bipirimidil-4-il]etenosulfonamida

$C_{24}H_{21}N_5O_5S$



netupitant

netupitant — 2-[3,5-bis(trifluoromethyl)phenyl]-*N*-methyl-*N*-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]-2-methylpropanamide

nétupitant — 2-[3,5-bis(trifluométhyl)phényl]-*N*,2-diméthyl-*N*-[4-(2-méthylphényl)-6-(4-méthylpipérazin-1-yl)pyridin-3-yl]propanamide

netupitant — 2-[3,5-bis(trifluometil)fenil]-*N*,2-dimetil-*N*-[4-(2-metilfenil)-6-(4-metilpiperazin-1-il)piridin-3-il]propanamida

$C_{30}H_{32}F_6N_4O$



omigapilum

omigapil — (dibenzo[*b*,*f*]oxepin-5-ylmethyl)(methyl)prop-2-yn-1-amine

omigapil — *N*-[(dibenzo[*b*,*f*]oxépin-10-yl)méthyl]-*N*-méthylprop-2-ynamine

omigapilo — *N*-[(dibenzo[*b*,*f*]oxepin-10-il)metil]-*N*-metilprop-2-inamina

$C_{19}H_{17}NO$



paclitaxelum poliglumexum

paclitaxel poliglumex

poly(L-glutamic acid) partly γ-esterified by (2*R*,3*S*)-3-benzamido-1-{[4,10β-bis(acetoxy)-2α-(benzoyloxy)-1,7β-dihydroxy-9-oxo-5,20-epoxytax-11-en-13α-yl]oxy}-1-oxo-3-phenylpropan-2-yl

paclitaxel poliglumex

poly(acide L-glutamique) partiellement γ-estérifié par du (1*R*)-1-[(*S*)-(benzoylamino)phénylméthyl]-2-[[(2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-6,12b-bis(acétyloxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tétraméthyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodécahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxét-9-yl]oxy]-2-oxoéthyle

paclitaxel poliglumex

poli(ácido L-glutámico) parcialmente γ-esterificado por (1*R*)-1-[(*S*)-(benzoilamino)fenilmetil]-2-[[(2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-6,12b-bis(acetiloxi)-12-(benzoiloxi)-4,11-dihidroxi-4a,8,13,13-tetrametil-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahidro-7,11-metano-1*H*-ciclodeca[3,4]benzo[1,2-*b*]oxet-9-il]oxi]-2-oxoetilo

$(C_{52}H_{56}N_2O_{16})_n \cdot (C_5H_7NO_3)_x$



pasireotidum

pasireotide

cyclo[(4*R*)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-*O*-benzyl-L-tyrosyl-L-phenylalanyl-)

pasiréotide

cyclo[-(4*R*)-4-[[(2-aminoéthyl)carbamoyl]oxy]-L-prolyl-(2*S*)-2-phénylglycyl-D-tryptophyl-L-lysyl-*O*-benzyl-L-tyrosyl-L-phénylalanyl-]

pasireotida

ciclo[-(4*R*)-4-[[(2-aminoetil)carbamoil]oxi]-L-prolil-(2*S*)-2-fenilglicil-D-triptofil-L-lisil-*O*-bencil-L-tirosil-L-fenilalanil-]

$C_{58}H_{66}N_{10}O_9$



pelitrexolum

pelitrexol (2*S*)-2-(5-{2-[(6*S*)-2-amino-4-oxo-1,4,5,6,7,8-hexahydropyrido=[2,3-*d*]pyrimidin-6-yl]ethyl}-4-methylthiophene-2-carboxamido)=pentanedioic acid

pélitrexol acide (2*S*)-2-[[[5-[2-[(6*S*)-2-amino-4-oxo-1,4,5,6,7,8-hexahydropyrido[2,3-*d*]pyrimidin-6-yl]éthyl]-4-méthylthiophén-2-yl]carbonyl]amino]pentanedioïque

pelitrexol ácido (2*S*)-2-[[[5-[2-[(6*S*)-2-amino-4-oxo-1,4,5,6,7,8-hexahidropirido[2,3-*d*]pirimidin-6-il]etil]-4-metiltiofen-2-il]carbonil]amino]pentanodioico

$C_{20}H_{25}N_5O_6S$



pruvanserinum

pruvanserin 7-{4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl}-1*H*-indole-3-carbonitrile

pruvansérine 1-[(3-cyano-1*H*-indol-7-yl)carbonyl]-4-[2-(4-fluorophényl)=éthyl]pipérazine

pruvanserina 1-[(3-ciano-1*H*-indol-7-il)carbonil]-4-[2-(4-fluorofenil)etil]piperazina

$C_{22}H_{21}FN_4O$



ramelteonum

ramelteon *N*-{2-[(8*S*)-1,6,7,8-tetrahydro-2*H*-indeno[5,4-*b*]furan-8-yl]=ethyl}propanamide

rameltéon (-)-*N*-[2-[(8*S*)-1,6,7,8-tétrahydro-2*H*-indéno[5,4-*b*]furan-8-yl]=éthyl]propanamide

ramelteòn *N*-[2-[(8*S*)-1,6,7,8-tetrahidro-2*H*-indeno[5,4-*b*]furan-8-il]=etil]propanamida

$C_{16}H_{21}NO_2$



ranibizumabum

ranibizumab	immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 γ1-chain), disulfide with human-mouse monoclonal rhuFAB V2 κ-chain
ranibizumab	immunoglobuline G1, anti-(facteur de croissance endothelial vasculaire humain) ; disulfure entre le fragment Fab de la chaîne γ1 et la chaîne κ de l'anticorps monoclonal de souris rhuFAB V2 humanisé
ranibizumab	inmunoglobulina G1, anti-(factor de crecimiento endotelial vascular humano) fragmento Fab (cadena γ1 del anticuerpo monoclonal humanizado de ratón rhuFAB V2), disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón rhuFAB V2

$C_{2158}H_{3282}N_{562}O_{681}S_{12}$

razaxabanum

razaxaban	1-(3-amino-1,2-benzisoxazol-5-yl)-*N*-{4-[2-(dimethylaminomethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-3-(trifluoromethyl)-1*H*-pyrazole-5-carboxamide
razaxaban	1-(3-amino-1,2-benzisoxazol-5-yl)-*N*-[4-[2-[(diméthylamino)méthyl]-1*H*-imidazol-1-yl]-2-fluorophényl]-3-(trifluorométhyl)-1*H*-pyrazole-5-carboxamide
razaxabán	1-(3-amino-1,2-bencisoxazol-5-il)-*N*-[4-[2-[(dimetilamino)metil]-1*H*-imidazol-1-il]-2-fluorofenil]-3-(trifluorometil)-1*H*-pirazol-5-carboxamida

$C_{24}H_{20}F_4N_8O_2$



rivaroxabanum

rivaroxaban — 5-chloro-*N*-({(5*S*)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide

rivaroxaban — 5-chloro-*N*-[[(5*S*)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phényl]oxazolidin-5-yl]méthyl]thiophène-2-carboxamide

rivaroxabán — 5-cloro-*N*-[[(5*S*)-2-oxo-3-[4-(3-oxomorfolin-4-il)fenil]oxazolidin-5-il]metil]tiofeno-2-carboxamida

$C_{19}H_{18}ClN_3O_5S$



sabarubicinum

sabarubicin — (7*S*,9*S*)-7-{[4-*O*-(3-amino-2,3,6-trideoxy-α-L-*lyxo*-hexopyranosyl)-2,6-dideoxy-α-L-*lyxo*-hexopyranosyl]oxy}-6,9,11-trihydroxy-9-(hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione

sabarubicine — (7*S*,9*S*)-7-[[4-*O*-(3-amino-2,3,6-tridésoxy-α-L-*lyxo*-hexopyranosyl)-2,6-didésoxy-α-L-*lyxo*-hexopyranosyl]oxy]-6,9,11-trihydroxy-9-(hydroxyacétyl)-7,8,9,10-tétrahydrotétracène-5,12-dione

sabarubicina — (7*S*,9*S*)-7-[[4-*O*-(3-amino-2,3,6-tridesoxi-α-L-*lixo*-hexopiranosil)-2,6-didesoxi-α-L-*lixo*-hexopiranosil]oxi]-6,9,11-trihidroxi-9-(hidroxiacetil)-7,8,9,10-tetrahidrotetraceno-5,12-diona

$C_{32}H_{37}NO_{13}$



solabegronum

solabegron — 3'-[(2-{[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}=ethyl)amino]biphenyl-3-carboxylic acid

solabégron — acide 3'-[[2-[[(2*R*)-2-(3-chlorophényl)-2-hydroxyéthyl]amino]=éthyl]amino]biphényle-3-carboxylique

solabegrón — ácido 3'-[[2-[[(2*R*)-2-(3-clorofenil)-2-hidroxietil]amino]=etil]amino]bifenilo-3-carboxílico

$C_{23}H_{23}ClN_2O_3$



tadekinigum alfa

tadekinig alfa	interleukin-18 binding protein (human gene IL18BP isoform a precursor)
tadékinig alfa	partie extracellulaire du récepteur de l'interleukine 18 humain
tadekinig alfa	fracción extracelular del receptor de la interleukina 18 humana

$C_{781}H_{1230}N_{216}O_{237}S_6$ (protein)

TPVSQTTTAA TASVRSTKDPH CPSQPPVFPA AKQCPALEVT
WPEVEVPLNG TLSLSCVACS RFPNFSILYW LGNGSFIEHL
PGRLWEGSTS RERGSTGTQL CKALVLEQLT PALHSTNFSC
VLVDPEQVVQ RHVVLAQLWA GLRATLPPTQ EALPSSHSSP
QQQG

tanaprogetum

tanaproget	5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2*H*-3,1-benzoxazin-6-yl)-1-methyl-1*H*-pyrrole-2-carbonitrile
tanaproget	5-(4,4-diméthyl-2-thioxo-1,4-dihydro-2*H*-3,1-benzoxazin-6-yl)-1-méthyl-1*H*-pyrrole-2-carbonitrile
tanaproget	5-(4,4-dimetil-2-tioxo-1,4-dihidro-2*H*-3,1-benzoxazin-6-il)-1-metil-1*H*-pirrol-2-carbonitrilo

$C_{16}H_{15}N_3OS$



taneptacoginum alfa

taneptacogin alfa	O^{344},$N^{\tau\text{-}193}$- cyclic hemiacetal obtained by the action of L-phenylalanyl L-phenylalanyl-L-arginine chloromethane on the blood coagulation factor VII (eptacog alfa) activated
taneptacogin alfa	O^{344},$N^{\tau\text{-}193}$-hemiacétal cyclique obtenu par action du L-phénylalanyl- L -phénylalanyl- L -arginylchlorométhane sur le facteur VIIa de coagulation humain (eptacog alfa) activé
taneptacogina alfa	O^{344},$N^{\tau\text{-}193}$-hemiacetal cíclico obtenido por acción del L-fenilalanil- L -fenilalanil-L-arginilclorometano sobre el factor VIIa de coagulación humano (eptacog alfa) activado

taprizosinum

taprizosin — *N*-{2-[4-amino-6,7-dimethoxy-5-(pyridin-2-yl)quinazolin-2-yl]-1,2,3,4-tetrahydroisoquinolin-5-yl}methanesulfonamide

taprizosine — *N*-[2-[4-amino-6,7-diméthoxy-5-(pyridin-2-yl)quinazolin-2-yl]-1,2,3,4-tétrahydroisoquinoléin-5-yl]méthanesulfonamide

taprizosina — *N*-[2-[4-amino-6,7-dimetoxi-5-(piridin-2-il)quinazolin-2-il]-1,2,3,4-tetrahidroisoquinolin-5-il]metanosulfonamida

$C_{25}H_{26}N_6O_4S$



teduglutidum

teduglutide — [2-glycine](1-33)-Peptide 2 analogue of human glucagon (GLP-2)

téduglutide — [2-glycine](1-33)-peptide du Peptide 2 Analogue du Glucagon humain (GLP-2)

teduglutida — [2-glicina]péptido(1-33) del péptido-2 análogo del glucagón humano

$C_{164}H_{252}N_{44}O_{55}S$

H–His–Gly–Asp–Gly–Ser–Phe–Ser–Asp–Glu–Met–Asn–Thr–
10
Ile–Leu–Asp–Asn–Leu–Ala–Ala–Arg–Asp–Phe–Ile–Asn–
20
Trp–Leu–Ile–Gln–Thr–Lys–Ile–Thr–Asp–OH
30

tocilizumabum

tocilizumab — immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide with human-mouse monoclonal MRA κ-chain, dimer

tocilizumab — immunoglobuline G1, anti-(récepteur de l'interleukine 6 humaine) ; dimère du disulfure entre la chaîne lourde et la chaîne-κ de l'anticorps monoclonal de souris MRA humanisé

tocilizumab — inmunoglobulina G1, anti-(receptor de la interleukina 6 humana) ; dímero del disulfuro entre la cadena pesada y la cadena -κ del anticuerpo monoclonal humanizado de ratón MRA

$C_{6428}H_{9976}N_{1720}O_{2018}S_{42}$

urtoxazumabum

urtoxazumab — immunogobulin, anti-(*Escherichia coli* Shiga-like toxin II B subunit) (human-mouse hybridoma HuVTm1.1 γ–chain V-D-J region), disulfur with human-mouse hybridoma HuVTm1.1 κ-chain V-J region, dimer

urtoxazumab — immunogobuline G1, anti-(sous-unité B de la toxine II analogue à la Shiga d'*Escherichia coli*) ; dimère du disulfure entre la chaîne γ et la chaîne κ de l'anticorps monoclonal de souris HuVTm1.1 humanisé

urtoxazumab — inmunogobulina G1, anti-(subunidad B de la toxina II análoga de la Shiga de *Escherichia coli*), dímero del disulfuro entre la cadena γ y la cadena κ del anticuerpo monoclonal de ratón HuVTm1.1 humanizado

$C_{6414}H_{9934}N_{1718}O_{2010}S_{40}$

valtorcitabinum

valtorcitabine — 4-amino-1-(3-*O*-L-valyl-2-deoxy-β-L-*erythro*-pentofuranosyl)-pyrimidin-2(1*H*)-one

valtorcitabine — 4-amino-1-[3-*O*-[(2*S*)-2-amino-3-méthylbutanoyl]-2-désoxy-β-L-*érythro*-pentofuranosyl]pyrimidin-2(1*H*)-one

valtorcitabina — 4-amino-1-(3-*O* -L-valil-2-desoxi-β-L-*eritro*-pentofuranosil)-pirimidin-2(1*H*)-ona

$C_{14}H_{22}N_4O_5$



vildagliptinum

vildagliptin — (2*S*)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile

vildagliptine — (2*S*)-1-[[(3-hydroxytricyclo[3.3.1.1^{3,7}]déc-1-yl)amino]acétyl= pyrrolidine-2-carbonitrile

vildagliptina — (2*S*)-1-[[(3-hidroxitriciclo[3.3.1.1^{3,7}]dec-1-il)amino]acetil]pirrolidina-2-carbonitrilo

$C_{17}H_{25}N_3O_2$



zanolimumabum

zanolimumab	immunoglobulin G1, anti-(human antigen CD4), heavy chain disulfide with the κ–chain of human monoclonal antibody 6G5.2, dimer
zanolimumab	immunoglobuline G1, anti-(antigène CD4 humain) ; dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal humain 6G5.2
zanolimumab	inmunoglobulina G1, anti-(antígeno CD4 humano) ; dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal humano 6G5.2



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 35
Dénominations communes internationales recommandées (DCI Rec.): Liste 35
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 35
(WHO Drug Information, Vol. 9, No. 3, 1995)

p. 26 **verteporfinum**

verteporfin	*insert the graphic formula by the folllowing:*
vertéporfine	*insérer la formule développée par la suivante:*
verteporfina	*insértese la fórmula desarollada por:*



Recommended International Nonproprietary Names (Rec. INN): List 50
Dénominations communes internationales recommandées (DCI Rec.): Liste 50
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 50
(WHO Drug Information, Vol. 17, No. 4, 2003)

p. 279 **lurasidonum**

lurasidona	*sustitúyase la descripción por la siguiente*

(3a*R*,4*S*,7*R*,7a*S*)-2-[[(1*R*,2*R*)-2-[[4-(1,2-bencisotiazol-3-il)piperazin-1-il]metil]ciclohexil]metil]hexahidro-4,7-metano-2*H*-isoindol-1,3-diona

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impairs des listes des DCIs proposées.

El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impairs des listes des DCIs proposées.

El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.